Investment Banking
Exclusive Financial Advisor to Endospan Ltd. on its Acquisition by Artivion, Inc.
May 20, 2026
Oppenheimer & Co. Inc. acted as Exclusive Financial Advisor to Endospan Ltd. on its acquisition by Artivion, Inc. for an upfront payment of $175,000,000 with potential earnout payments that could increase ultimate transaction value to $375,000,000
Endospan Ltd., a privately held medical device company pioneering endovascular repair technologies for aortic arch disease, announced that Artivion, Inc. exercised its option to acquire the Company for up to $375.0 million, consisting of $175.0 million payable at closing and up to $200.0 million in contingent payments tied to commercial milestones. The transaction follows the recent U.S. Food and Drug Administration (“FDA”) premarket approval (“PMA”) of Endospan’s NEXUS® Aortic Arch System, the first branched endovascular stent graft system approved in the United States for the minimally invasive treatment of aortic arch disease, including chronic aortic dissections.
Headquartered in Herzliya, Israel, Endospan is a pioneer in endovascular repair solutions for aortic arch disease and dissections. The Company developed the NEXUS Stent Graft System, the first endovascular off-the-shelf system designed to treat complex aortic arch disease, addressing a critically underserved patient population that historically had limited treatment options beyond highly invasive open-chest surgery. Along with their US FDA approval announced April 2026, Endospan has received CE Mark approval for their NEXUS platform and established itself as a leader in minimally invasive aortic arch repair technologies.
Artivion, headquartered in Atlanta, Georgia, is a leading cardiac and vascular surgery company focused on the treatment of aortic disease through a portfolio of aortic stent grafts, surgical sealants, mechanical heart valves, and implantable cardiac and vascular tissues marketed globally.
Oppenheimer & Co. Inc. served as exclusive financial advisor to Endospan in connection with the transaction.
Healthcare Life Sciences Investment Banking
Name:
Eric Tansky
Title:Managing Director, Head of Medical Technology Banking
Name:
Michael A. Margolis, R.Ph.
Title:Senior Managing Director, Head of Healthcare Life Sciences Investment Banking
Healthcare M&A Investment Banking
Name:
Jonathan Lasker
Title:Managing Director, Healthcare M&A Investment Banking
Technology Investment Banking
Name:
Guy Cohen
Title:Managing Director, Israel & EMEA Technology
DISCLOSURES
This notice is provided for informational purposes only and is not intended as a recommendation or an offer or solicitation for the purchase or sale of any security or financial instrument. Nothing contained herein shall constitute an offer or solicitation to buy or sell any securities discussed herein in any jurisdiction where such offer or solicitation would be prohibited.
This notice may contain statistical data cited from third-party sources believed to be reliable, but Oppenheimer & Co. Inc. does not represent that any such third-party statistical information is accurate or complete, and it should not be relied upon as such. All market prices, data and other information are not warranted as to completeness or accuracy and are subject to change without notice.
Oppenheimer & Co. Inc. Transacts Business on all Principal US Exchanges and is a Member of SIPC 8933783.1